- Home
- AGIO vs TUYA Comparison
AGIO vs TUYA Comparison
Compare AGIO & TUYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- TUYA
- Stock Information
- Founded
- AGIO 2007
- TUYA 2014
- Country
- AGIO United States
- TUYA China
- Employees
- AGIO N/A
- TUYA N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- TUYA Computer Software: Prepackaged Software
- Sector
- AGIO Health Care
- TUYA Technology
- Exchange
- AGIO Nasdaq
- TUYA Nasdaq
- Market Cap
- AGIO 1.4B
- TUYA 1.2B
- IPO Year
- AGIO 2013
- TUYA 2021
- Fundamental
- Price
- AGIO $27.32
- TUYA $2.32
- Analyst Decision
- AGIO Buy
- TUYA
- Analyst Count
- AGIO 8
- TUYA 0
- Target Price
- AGIO $56.00
- TUYA N/A
- AVG Volume (30 Days)
- AGIO 524.5K
- TUYA 1.7M
- Earning Date
- AGIO 05-01-2025
- TUYA 05-19-2025
- Dividend Yield
- AGIO N/A
- TUYA 4.69%
- EPS Growth
- AGIO N/A
- TUYA N/A
- EPS
- AGIO 11.45
- TUYA 0.01
- Revenue
- AGIO $37,035,000.00
- TUYA $298,617,000.00
- Revenue This Year
- AGIO $40.62
- TUYA $22.34
- Revenue Next Year
- AGIO $216.26
- TUYA $18.11
- P/E Ratio
- AGIO $2.39
- TUYA $266.42
- Revenue Growth
- AGIO 25.96
- TUYA 29.84
- 52 Week Low
- AGIO $23.42
- TUYA $1.28
- 52 Week High
- AGIO $62.58
- TUYA $4.63
- Technical
- Relative Strength Index (RSI)
- AGIO 41.34
- TUYA 46.06
- Support Level
- AGIO $27.78
- TUYA $2.21
- Resistance Level
- AGIO $31.55
- TUYA $2.46
- Average True Range (ATR)
- AGIO 1.38
- TUYA 0.14
- MACD
- AGIO -0.03
- TUYA 0.06
- Stochastic Oscillator
- AGIO 2.98
- TUYA 69.32
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About TUYA Tuya Inc. each representing one
Tuya Inc is an IoT cloud development platform with a mission to build an IoT developer ecosystem and enable everything to be smart. The Company has pioneered a purpose-built IoT cloud development platform that delivers a full suite of offerings, including platform-as-a-service (PaaS) and Software-as-a-service (SaaS), to businesses and developers. Through its IoT cloud development platform, It has enabled developers to activate a vibrant IoT ecosystem of brands, OEMs, partners, and end users to engage and communicate through a broad range of smart devices. The company's revenue is derived from the PRC.